A Case of Adult-Onset Vitelliform Dystrophy Treated with Intravitreal Injection of Bevacizumab

Sang Woo Moon; Ho Young Lee; Il Han Yun; Sung Hyup Lim

doi:10.3341/jkos.2014.55.7.1093

Journal List > J Korean Ophthalmol Soc > v.55(7) > 1009735

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Moon, Lee, Yun, and Lim: A Case of Adult-Onset Vitelliform Dystrophy Treated with Intravitreal Injection of Bevacizumab

Case Report

J Korean Ophthalmol Soc 2014;55(7):1093-1098.

Published online: 30 August 2014

DOI: https://doi.org/10.3341/jkos.2014.55.7.1093

A Case of Adult-Onset Vitelliform Dystrophy Treated with Intravitreal Injection of Bevacizumab

Sang Woo Moon, MD^1,², Ho Young Lee, MD³, Il Han Yun, MD, PhD¹, Sung Hyup Lim, MD^1,²

¹Department of Ophthalmology, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea

²Therapeutics Center for Ocular Neovascular Disease, Busan, Korea

³Shinsegae Eye Clinic, Busan, Korea

Address reprint requests to Sung Hyup Lim, MD, Department of Ophthalmology, Inje University Busan Paik Hospital, #75 Bokji-ro, Busanjin-gu, Busan 614-735, Korea, Tel: 82-51-890-6015, Fax: 82-51-890-6329, E-mail: klimt99@naver.com

Received 26 October 2013 Revised 20 January 2014 Accepted 9 June 2014

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose

To report a patient diagnosed with adult-onset vitelliform dystrophy (AOVD) who received an intravitreal injection of bevacizumab in both eyes.

Case summary

A 47-year-old female presented with blurred vision and metamorphopsia in both eyes. On color fundus photograph, small, round, yellowish dots on the foveola and subreitnal fluid were observed. Optical coherence tomography (OCT) showed thick hyperreflective structures in the retinal pigment epithelium (RPE) layer with serous retinal detachment and subretinal fluid. Despite an intravitreal injection of bevacizumab on both eyes, anatomical improvement was not observed on fundus photography and OCT.

Keywords: Bevacizumab, Vitelliform macular dystrophy

References

1. Do P, Ferrucci S. Adult-onset foveomacular vitelliform dystrophy. Optometry. 2006; 77:156–66.

2. Funk M, Kriechbaum K, Prager F, et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci. 2009; 50:1025–32.

3. Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, et al. Twelvemonth safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol. 2008; 246:81–7.

4. Kreutzer TC, Alge CS, Wolf AH, et al. Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol. 2008; 92:351–5.

5. Rabena MD, Pieramici DJ, Castellarin AA, et al. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina. 2007; 27:419–25.

6. Matsumoto Y, Freund KB, Peiretti E, et al. Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease. Retina. 2007; 27:426–31.

7. Lee JY, Lim J, Chung H, et al. Spectral domain optical coherence tomography in a patient with adult-onset vitelliform dystrophy treated with intravitreal bevacizumab. Ophthalmic Surg Lasers Imaging. 2009; 40:319–21.

8. Petrukhin K, Koisti MJ, Bakall B, et al. Identification of the gene responsible for Best macular dystrophy. Nat Genet. 1998; 19:241–7.

9. Marmorstein AD, Marmorstein LY, Rayborn M, et al. Bestrophin, the product of the Best vitelliform macular dystrophy gene (VMD2), localizes to the basolateral plasma membrane of the retinal pigment epithelium. Proc Natl Acad Sci U S A. 2000; 97:12758–63.

10. Sun H, Tsunenari T, Yau KW, Nathans J. The vitelliform macular dystrophy protein defines a new family of chloride channels. Proc Natl Acad Sci U S A. 2002; 99:4008–13.

11. Boon CJ, Klevering BJ, Leroy BP, et al. The spectrum of ocular phenotypes caused by mutation in the BEST 1 gene. Prog Retin Eye Res. 2009; 28:187–205.

12. Booij JC, Boon CJ, van SChooneveld MJ, et al. Course of visual decline in relation to the BEST1 genotype in vitelliform macular dystrophy. Ophthalmology. 2010; 117:1415–22.

13. Jarc-Vidmar M, Kraut A, Hawlina M. Fundus autofluorescence imaging in Best's vitelliform dystrophy. Klin Monatsbl Augenheilkd. 2003; 220:861–7.

14. Gass JDM. Stereoscopic atlas of macular diseases: diagnosis and treatment. 4th ed.St. Louis: Mosby;1997. p. 304–11.

15. Deutman AF, Hoyng CB. Macular dystrophies. In : Ryan SJ, Ogden TE, Hinton DR, editors. Retina. 3rd.2. St. Louis: Mosby;2001. p. 1210–57.

16. Spaide RF, Noble K, Morgan A, Freund KB. Vitelliform macular dystrophy. Ophthalmology. 2006; 113:1392–400.

17. Montero JA, Ruiz-Moreno JM, De La Vega C. Intravitreal bevacizumab for adult-onset vitelliform dystrophy: a case report. Eur J Ophthalmol. 2007; 17:983–6.

18. Abengoechea-Hernandez S, Elizalde-Montagut J, Fideliz de la Paz-Dalisay M. Photodynamic therapy in adult-onset foveomacular vitelliform dystrophy. Arch Soc Esp Oftalmol. 2007; 82:117–20.

Figure 1.

Color fundus photograph of a 47-year-old female showing a small, round, yellowish dot at the site of the foveola or a tiny honeycomb structure centrally (A, B). In fluorescence angiography reveals early blockage and late intense hyperfluorescent circles with hypofluorescent central zones (C, D).

Figure 2.

Right eye optical coherence tomography (OCT) represents thick hyperreflective structures in the retinal pigment epithelium (RPE) layer and serous retinal detachment and subretinal fluid. OCT after the intravitreal bevacizumab showing no difference of subretinal fluid volume or extent of serous retinal detachment and hyperreflective lesions. IVAI = intravitreal avastin injection.

Figure 3.

Left eye optical coherence tomography (OCT) also represents abnormal findings as described above on the right eye. OCT was performed after the intravitreal bevacizumab, there were also no difference of subretinal fluid volume or extent of serous retinal detachment and hyperreflective lesions. IVAI = intravitreal avastin injection.

Figure 4.

Electrooculography (EOG) showed decrease in the Arden ratio (light-dark ratio), 1.16 in the right eye and 1.25 in the left eye. R-T = right trough; R-P = right peak; L-T = left trough; L-P = left peak.

TOOLS

Similar articles